Industry subject matter experts spoke about the challenges of turning complex molecules into medicines patients can reliably use.
|Articles|December 1, 2016
- Pharmaceutical Technology-12-01-2016
- Volume 2016 Supplement
- Issue 4
Pharmaceutical Technology, 2016 Corporate Capabilities Supplement (PDF)
Click the title above to open the Pharmaceutical Technology 2016 Corporate Capabilities Supplement in an interactive PDF format.
Advertisement
Advertisement
Related to this article
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Potent APIs Amplify Carryover Risk: AAPS PharmSci 360 2026
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5